Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of SEK 408.85 million. The enterprise value is 372.03 million.

Market Cap	408.85M
Enterprise Value	372.03M

Important Dates

The next estimated earnings date is Thursday, May 15, 2025.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Oncopeptides AB has 215.19 million shares outstanding. The number of shares has increased by 84.14% in one year.

Current Share Class	n/a
Shares Outstanding	215.19M
Shares Change (YoY)	+84.14%
Shares Change (QoQ)	+2.99%
Owned by Insiders (%)	0.30%
Owned by Institutions (%)	20.72%
Float	183.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12.92
PB Ratio	7.53
P/TBV Ratio	7.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.31
EV / Sales	11.76
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.43

Financial Position

The company has a current ratio of 4.23, with a Debt / Equity ratio of 2.61.

Current Ratio	4.23
Quick Ratio	3.74
Debt / Equity	2.61
Debt / EBITDA	n/a
Debt / FCF	-0.54
Interest Coverage	-22.32

Financial Efficiency

Return on equity (ROE) is -512.51% and return on invested capital (ROIC) is -91.97%.

Return on Equity (ROE)	-512.51%
Return on Assets (ROA)	-73.20%
Return on Invested Capital (ROIC)	-91.97%
Return on Capital Employed (ROCE)	-146.54%
Revenue Per Employee	395,600
Profits Per Employee	-3.56M
Employee Count	80
Asset Turnover	0.13
Inventory Turnover	0.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -36.24% in the last 52 weeks. The beta is -0.55, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-0.55
52-Week Price Change	-36.24%
50-Day Moving Average	1.70
200-Day Moving Average	1.85
Relative Strength Index (RSI)	56.42
Average Volume (20 Days)	679,146

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of SEK 31.65 million and -284.61 million in losses. Loss per share was -1.71.

Revenue	31.65M
Gross Profit	28.99M
Operating Income	-282.59M
Pretax Income	-284.21M
Net Income	-284.61M
EBITDA	-280.12M
EBIT	-282.59M
Loss Per Share	-1.71

Full Income Statement

Balance Sheet

The company has 178.54 million in cash and 141.72 million in debt, giving a net cash position of 36.82 million or 0.17 per share.

Cash & Cash Equivalents	178.54M
Total Debt	141.72M
Net Cash	36.82M
Net Cash Per Share	0.17
Equity (Book Value)	54.29M
Book Value Per Share	0.25
Working Capital	165.73M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -260.57 million and capital expenditures -357,000, giving a free cash flow of -260.93 million.

Operating Cash Flow	-260.57M
Capital Expenditures	-357,000
Free Cash Flow	-260.93M
FCF Per Share	-1.21

Full Cash Flow Statement

Margins

Gross Margin	91.59%
Operating Margin	-892.91%
Pretax Margin	-898.03%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-84.14%
Shareholder Yield	-84.14%
Earnings Yield	-69.61%
FCF Yield	-63.82%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oncopeptides AB has an Altman Z-Score of -33.65. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-33.65
Piotroski F-Score	n/a